drugset
drugset / Trial / NCT03427866

Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.

NCT03427866 ↗

Phase 2 Completed 44 enrolled Massachusetts General Hospital Incyte Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a drug called Ruxolitinib as a possible treatment for Myelofibrosis.

Timeline

Start
2018-08-28
Primary completion
2024-05-01
Completion
2025-05-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule 10 mg Oral

Indications

myelofibrosis